CAR T-Cell Therapy Program
Relapsed/Refractory Multiple Myeloma
DevelopmentActive
Key Facts
Indication
Relapsed/Refractory Multiple Myeloma
Phase
Development
Status
Active
Company
About Dr. Reddy's Laboratories
Founded in 1984, Dr. Reddy's Laboratories has evolved from an API manufacturer into a global pharmaceutical leader with a mission to accelerate access to affordable and innovative medicines. Its core strategy balances a robust generics and biosimilars business with targeted investments in complex generics, innovative therapies, and strategic partnerships. Key recent achievements include the first-to-market launch of a generic semaglutide injection in India, expansion of its biosimilar portfolio in developed markets, and a stated goal to touch 1.5 billion patient lives by 2030.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| inobrodib + Pd (InoPd) | CellCentric | Phase 1/2 |
| TECVAYLI + DARZALEX FASPRO | Johnson and Johnson Innovative Medicine | Approved |
| HDP-101 | Heidelberg Pharma | Phase 1/2a |
| CT053 | CARsgen Therapeutics | Phase 1b/2 |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| ABBV-383 | AbbVie | Phase 1 |
| Blenrep (belantamab mafodotin) | GSK plc | Phase III |
| bri-cel (BAY 2413334) | Bayer | Phase I |
| Ciltacabtagene autoleucel (Carvykti) | Genscript Biotech | Approved / Phase 3 |
| CAR-T Cell Therapy | Dr. Reddy's Laboratories | Discovery/Development |
| Anitocabtagene Autoleucel (anito-cel) | Arcellx | Phase 2 |